Torren Management’s Neurocrine Biosciences NBIX Stock Holding History

Torren Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-53	Closed	-$7.52K	–	1277
2025 Q4	$7.52K	Buy	+53	New	+$7.68K	﹤0.01%	835

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Torren Management's NBIX Position: Q1 2026 in Review

Torren Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 53 shares — an estimated $7.52K sold.

Torren Management first reported a position in NBIX in Q4 2025 and held it in 1 quarter. The position peaked at $7.52K in Q4 2025. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Torren Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Torren Management sold 53 Neurocrine Biosciences shares in Q1 2026, an estimated $7.52K.
Torren Management first reported a position in Neurocrine Biosciences in Q4 2025 and held it in 1 quarter.
Torren Management's Neurocrine Biosciences position peaked at $7.52K in Q4 2025.
696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.